Objective: To explore the clinical effect of autologous concentrated growth factor (CGF) in reducing hair loss during the shedding period after hair transplantation. Methods: A total of 80 patients who underwent hair transplantation in our hospital from May 2023 to December 2024 were selected as the research subjects and randomly divided into a control group and an observation group, with 40 cases in each group. The control group received conventional surgery and postoperative care, while the observation group was given local CGF injection intervention during the operation and one month after the operation on the basis of the control group. The hair loss, hair density, hair follicle survival rate, and adverse reactions of the two groups were compared. Results: At 1 month, 2 months, and 3 months after the operation, the number of hair loss in the observation group was less than that in the control group, and the number of existing hair in the recipient area was more than that in the control group (P < 0.05). At 12 months after the operation, the hair density and hair follicle survival rate in the observation group were higher than those in the control group (P < 0.05). During the treatment period, both groups had a small number of mild adverse reactions, and no severe adverse reactions occurred (P > 0.05). All mild adverse reactions were relieved spontaneously within 1 to 3 days without special treatment and did not affect the treatment process. Conclusion: Local injection of autologous concentrated growth factor can effectively reduce the number of hair loss during the shedding period after hair transplantation, increase the postoperative hair density and survival rate, and has high safety, which is worthy of clinical promotion and application.